Shots:
Myriad Genetics to launch the Prolaris + AI Test, with the new AI metric available for all Prolaris Biopsy Tests in the US from May 29, 2026 excl. New York; approval in NY is expected soon
A validation study of 998 pts for model training & 296 pts for validation, demonstrated that AI-GUR independently…
Shots:
Roche has entered into a definitive merger agreement to acquire PathAI, building on their 2021 partnership, which scaled up in 2024 to incl. the development of AI-enabled companion diagnostic algorithms
As per the deal, Roche will acquire PathAI for $750M upfront & ~$300M in additional milestone payments; closing is expected in H2’26
The acquisition…
Imagene AI has entered into a collaboration with Daiichi Sankyo to advance biomarker discovery and response prediction across oncology drug development programs
Under the collaboration, Daiichi Sankyo will leverage Imagene’s OI Suite, powered by the CanvOI foundation model, to integrate H&E and IHC whole-slide images with molecular and clinical data to enhance biomarker identification and…
Shots:
ClearStain debuted at SITC 2025 as a workflow-changing innovation, delivering high-quality virtual H&E images from unstained slides to improve tumor identification, reduce sequencing failures, preserve tissue, and accelerate molecular and precision oncology workflows
By enabling direct visualization and annotation of the exact tissue destined for sequencing, ClearStain helps pathologists and molecular labs maximize tumor purity, minimize impurities,…
Paige is a global digital pathology founded in 2017 by Thomas Fuchs, Dr. Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The company involves computational pathology products that are targeted for patients and their care teams for effective, more informed treatment decisions. Paige has developed a platform to deliver novel technology to pathologists to…

